Pfizer (PFE) Stock Drops 3% as CFO Dave Denton Exits in August

TLDR

• Pfizer CFO Dave Denton will leave the company on August 15 to return to the consumer goods industry
• PFE stock fell around 3% on the news, trading near $25.10
• Cecile Guegan named interim CFO; she has held finance roles at Pfizer for over 20 years
• Scotiabank analyst raised concerns over 2026 forecasts, succession planning, and Pfizer’s obesity drug market entry timing
• Pfizer will search internally and externally for a permanent CFO replacement

Pfizer (PFE) stock dropped around 3% on Thursday after the company announced CFO Dave Denton will step down on August 15, with the stock trading near $25.10 in early trading.

Pfizer Inc., PFE

Denton is leaving to return to the consumer goods industry, ending a four-year run at the drugmaker. He joined Pfizer in 2022, having previously served as CFO at CVS Health for nearly 20 years before a stint at Lowe’s.

Cecile Guegan has been named interim CFO. She is currently senior vice president of finance for Pfizer’s global biopharmaceuticals business and has worked in finance roles at Pfizer for over two decades.

Denton and Guegan will work together on the handover before his August departure.

Scotiabank analyst Louise Chen flagged the news as a concern for investors. She pointed to questions around Pfizer’s 2026 guidance, succession planning, and the fact that the transition comes as Pfizer prepares to enter the obesity drug market.

The timing hasn’t gone unnoticed on Wall Street. Pfizer is at a pivotal stage, and losing its finance chief now adds a layer of uncertainty the market clearly isn’t comfortable with.

A Busy Four Years

Denton’s tenure coincided with one of Pfizer’s most active dealmaking periods. The company used the revenue surge from its COVID-19 vaccine and antiviral treatment Paxlovid to fund a string of acquisitions.

Those deals included cancer drug specialist Seagen, migraine treatment maker Biohaven, and weight-loss drug developer Metsera. The goal was to cushion the blow from falling COVID product sales and upcoming patent expirations on key drugs.

CEO Albert Bourla has set a target of adding $20 billion in revenue by 2030. However, he has said he expects the company to return to meaningful growth only after 2028.

Stock Performance in Context

Pfizer stock has nearly halved since Denton took the CFO role in 2022. Investor concerns have centered on whether the acquisitions and internal pipeline can make up for the revenue gap left by declining COVID-related sales.

Despite that longer-term slide, PFE had gained roughly 4% year-to-date through Wednesday’s close before Thursday’s drop.

Pfizer said it will run both an internal and external search for a permanent CFO.

Denton’s exit adds to the list of leadership transitions at major pharma companies this year. For now, Guegan steps into the interim role as Pfizer navigates its next chapter.

The post Pfizer (PFE) Stock Drops 3% as CFO Dave Denton Exits in August appeared first on CoinCentral.